Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0001558370-23-014866
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | -$20.68M | -$17.54M | -$12.20M | -$3.01M |
| EPS Diluted | -$1.61 | -$0.08 | -$0.07 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end
